MedTrace Logo

ALPN-101 in Steroid-resistant or Steroid-refractory Acute GVHD

NCT04227938 · Status: TERMINATED · Phase: PHASE1 · Type: INTERVENTIONAL · Enrollment: 1

Last updated 2023-08-28

No results posted yet for this study

Summary

The Balance study will assess the safety, tolerability, and efficacy of an investigational drug called ALPN-101 in adults with steroid-resistant or steroid-refractory acute graft versus host disease (aGVHD).

Conditions

  • Graft Vs Host Disease

Interventions

DRUG

ALPN-101

A single dose of ALPN-101 will be administered via intravenous infusion.

Sponsors & Collaborators

  • Alpine Immune Sciences, Inc.

    lead INDUSTRY

Principal Investigators

  • Jan Hillson, MD · Alpine Immune Sciences, Inc.

Study Design

Allocation
NA
Purpose
TREATMENT
Masking
NONE
Model
SINGLE_GROUP

Eligibility

Min Age
18 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2020-05-11
Primary Completion
2020-05-21
Completion
2020-05-21
FDA Drug
Yes

Countries

  • United States

Study Locations

More Related Trials

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT04227938 on ClinicalTrials.gov